Viela Bio, Inc.
(NASDAQ : VIE)

( )
VIE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.55%293.851.4%$595.18m
AMGNAmgen, Inc.
0.85%235.991.3%$497.59m
GILDGilead Sciences, Inc.
0.72%67.631.0%$369.81m
REGNRegeneron Pharmaceuticals, Inc.
-0.37%372.162.6%$302.06m
VRTXVertex Pharmaceuticals, Inc.
0.25%220.551.9%$275.13m
CLVSClovis Oncology, Inc.
14.59%13.4314.7%$241.85m
ILMNIllumina, Inc.
0.44%321.993.5%$235.54m
ARWRArrowhead Pharmaceuticals, Inc.
-1.32%67.3211.4%$205.58m
ALXNAlexion Pharmaceuticals, Inc.
2.71%112.472.0%$202.78m
AAgilent Technologies, Inc.
1.73%84.861.6%$165.50m
EXASEXACT Sciences Corp.
0.29%85.4224.0%$161.05m
GBTGlobal Blood Therapeutics, Inc.
-1.99%76.896.0%$140.66m
BLUEbluebird bio, Inc.
-3.36%84.0514.2%$136.75m
BOLDAudentes Therapeutics, Inc.
-0.12%59.371.4%$134.85m
SGENSeattle Genetics, Inc.
0.83%112.266.1%$128.97m

Company Profile

Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.